LUTATHERA (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
LUTATHERA
Date registered
Evaluation commenced
Decision date
Approval time
248 (255 working days)
Active ingredients
lutetium (177Lu) oxodotreotide
Registration type
NCE/NBE
Indication
LUTATHERA is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumours in adults.